201 related articles for article (PubMed ID: 37516063)
1. First evidence of the incorporation of daprodustat and other hypoxia-inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis.
Ishii H; Shibuya M; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Yamada M; Leung GN
J Pharm Biomed Anal; 2023 Oct; 235():115600. PubMed ID: 37516063
[TBL] [Abstract][Full Text] [Related]
2. Long-term monitoring of IOX4 in horse hair and its longitudinal distribution with segmental analysis using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometry for the purpose of doping control.
Ishii H; Shibuya M; So YM; Wong JKY; Ho ENM; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Yamada M; Leung GN
Drug Test Anal; 2022 Jul; 14(7):1244-1254. PubMed ID: 35195358
[TBL] [Abstract][Full Text] [Related]
3. Segmental analysis and long-term monitoring of vadadustat in equine hair for the purpose of doping control.
Ishii H; Shibuya M; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Yamada M; Leung GN
J Anal Toxicol; 2023 Sep; 47(7):623-631. PubMed ID: 37632695
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies of hypoxia inducible factor-prolyl hydroxylase inhibitors daprodustat, desidustat, and vadadustat for equine doping control.
Philip M; Karakka Kal AK; Subhahar MB; Karatt TK; Mathew B; Perwad Z
Drug Test Anal; 2022 Feb; 14(2):317-348. PubMed ID: 34714596
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometer for the purpose of doping control.
Ishii H; Shibuya M; So YM; Wong JKY; Ho ENM; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Yamada M; Leung GN
Drug Test Anal; 2022 Feb; 14(2):233-251. PubMed ID: 34612014
[TBL] [Abstract][Full Text] [Related]
6. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
Doggrell SA
Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations.
Sackeyfio A; Lopes RD; Kovesdy CP; Cases A; Mallett SA; Ballew N; Keeley TJ; Garcia-Horton V; Ayyagari R; Camejo RR; Johansen KL; Sutton AJ; Dasgupta I
Clin Kidney J; 2024 Jan; 17(1):sfad298. PubMed ID: 38250252
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Chen H; Cheng Q; Wang J; Zhao X; Zhu S
J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Study of Vadadustat and High-Resolution Mass Spectrometric Characterization of its Novel Metabolites in Equines for the Purpose of Doping Control.
Ishii H; Shibuya M; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Sato F; Kuroda T; Yamada M; Leung GN
Curr Drug Metab; 2022; 23(10):850-865. PubMed ID: 36017833
[TBL] [Abstract][Full Text] [Related]
10. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
[TBL] [Abstract][Full Text] [Related]
11. Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor.
Adams DF; Watkins MS; Durette L; Laliberté J; Goulet F; Debien E; Frazier KS; Mellal N; Chen L; Shi W; Thomas R; Hu E
Toxicol Pathol; 2020 Feb; 48(2):362-378. PubMed ID: 31640478
[TBL] [Abstract][Full Text] [Related]
12. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Gupta N; Wish JB
Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
[TBL] [Abstract][Full Text] [Related]
14. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
15. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
Singh AK; Carroll K; McMurray JJV; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; DiMino TL; Kler L; Meadowcroft AM; Taft L; Perkovic V;
N Engl J Med; 2021 Dec; 385(25):2313-2324. PubMed ID: 34739196
[TBL] [Abstract][Full Text] [Related]
16. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV;
N Engl J Med; 2021 Dec; 385(25):2325-2335. PubMed ID: 34739194
[TBL] [Abstract][Full Text] [Related]
17. A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.
Tsubakihara Y; Akizawa T; Nangaku M; Onoue T; Yonekawa T; Matsushita H; Endo Y; Cobitz A
Ther Apher Dial; 2020 Apr; 24(2):108-114. PubMed ID: 31306555
[TBL] [Abstract][Full Text] [Related]
18. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.
Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV
BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
[TBL] [Abstract][Full Text] [Related]
20. The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases.
Imai E; Imai A
Intern Med; 2023 Nov; ():. PubMed ID: 37926547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]